Inozyme Pharma Inc logo

Inozyme Pharma Inc Share Price Today (NASDAQ: INZY)

Inozyme Pharma Inc share price is $4 & ₹343.37 as on 29 Jun 2025 IST

$4

▲

0.01

(0.25%)

Market is closed - opens 7 PM, 14 Jul 2025

Bell Icon

The stock has been delisted from the stock exchange on 30 Jun 2025

View live Inozyme Pharma Inc share price in Dollar and Rupees. Guide to invest in Inozyme Pharma Inc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Inozyme Pharma Inc, along with analyst recommendations, forecasts, and comprehensive financials.

Inozyme Pharma Inc (INZY) Key Statistics

in dollars & INR

Previous Close
$3.99
Open
$4.0
Market Capitalization
$257.6M
Today's Volume
$1.5M
Revenue TTM
$0.0
EBITDA
$-104.7M
Earnings Per Share (EPS)
$-1.68
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-141.69%

How to invest in Inozyme Pharma Inc Stock (INZY) from India?

It is very easy for Indian residents to invest directly in Inozyme Pharma Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Inozyme Pharma Inc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Inozyme Pharma Inc or INZY on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Inozyme Pharma Inc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Inozyme Pharma Inc shares which would translate to 0.215 fractional shares of Inozyme Pharma Inc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Inozyme Pharma Inc, in just a few clicks!

Global Institutional Holdings in Inozyme Pharma Inc

  • Adage Capital Partners Gp LLC

    7.99%

  • Pivotal bioVenture Partners Investment Advisor LLC

    6.96%

  • Sofinnova Ventures

    6.63%

  • Affinity Asset Advisors, LLC

    5.99%

  • BlackRock Inc

    5.80%

  • Rock Springs Capital Management LP

    5.34%

Analyst Recommendation on Inozyme Pharma Inc

Rating
Trend

Buy

    92%Buy

    7%Hold

    0%Sell

Based on 13 Wall street analysts offering stock ratings for Inozyme Pharma Inc(by analysts ranked 0 to 5 stars)

About Inozyme Pharma Inc

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Organization
Inozyme Pharma Inc
Employees
67
CEO
Dr. Douglas A. Treco Ph.D.
Industry
Health Technology

Management People of Inozyme Pharma Inc

NameTitle
Dr. Douglas A. Treco Ph.D.
CEO & Chairman
Mr. Axel Bolte M.B.A., M.Sc.
Co-Founder, Senior Advisor & Director
Mr. Sanjay S. Subramanian M.B.A., M.S.
CFO, Head of Business Development, Principal Accounting Officer & Corporate Secretary
Dr. Matthew Winton Ph.D.
Senior VP & COO
Dr. Demetrios Braddock M.D., Ph.D.
Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer
Dr. Yves Sabbagh Ph.D.
Senior VP, Chief Scientific Officer & Chair of the Scientific Advisory Board
Mr. Stefan Riley
Director of Investor Relations
Ms. Gayle Gironda
Senior VP & Chief People Officer
Mr. Stephen J. Di Palma M.B.A.
Consultant
Dr. Petra Duda M.D., Ph.D.
Chief Medical Officer

Important FAQs about investing in INZY Stock from India :

Can Indians buy Inozyme Pharma Inc shares?

Yes, Indians can invest in the Inozyme Pharma Inc (INZY) from India.

With INDmoney, you can buy Inozyme Pharma Inc at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Inozyme Pharma Inc at zero transaction cost.

How can I buy Inozyme Pharma Inc shares from India?

It is very easy to buy Inozyme Pharma Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Inozyme Pharma Inc (INZY) be purchased?

Yes, you can buy fractional shares of Inozyme Pharma Inc with INDmoney app.

What are the documents required to start investing in Inozyme Pharma Inc stocks?

To start investing in Inozyme Pharma Inc, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is today's market capitalisation of Inozyme Pharma Inc?

Today's market capitalisation of Inozyme Pharma Inc INZY is 257.6M

Who is the Chief Executive Officer (CEO) of Inozyme Pharma Inc ?

Dr. Douglas A. Treco Ph.D. is the current Chief Executive Officer (CEO) of Inozyme Pharma Inc.